Printed from Voxsanity (voxsanity.com.au) — NCT07640932 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07640932
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 19 years or older.
- People who have been diagnosed with extensive-stage small cell lung cancer (a type of lung cancer that has spread), confirmed through a tissue or cell sample analysis.
- People whose cancer has continued to grow or spread after receiving at least one prior chemotherapy treatment containing platinum, including those whose cancer returned or worsened within 6 months of completing chemotherapy, or those in specific earlier-stage situations where the cancer either responded or did not respond to platinum-based treatment (confirm with trial site for which group applies).
- People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning they are fully active, or have some limitations but are still up and about for more than half the day).
- People who have at least one area of cancer that can be measured on scans, according to standard measurement guidelines.
- People with a life expectancy of at least 12 weeks (3 months).
- People whose blood, kidney, liver, and metabolic test results fall within acceptable ranges, tested within the 14 days before joining the trial (confirm with trial site for specific values).
- People who are willing to provide tissue samples (unstained slides — at least 5, ideally 15) from either stored or newly collected biopsy material for research purposes.
- Women who could become pregnant must have a negative pregnancy test (urine) at the start of the trial, and if that result is unclear or positive, a negative blood pregnancy test is also required.
- Women who could become pregnant must agree to use effective contraception for the duration of the study.
- Men who could father a child must agree to use effective contraception for the duration of the study.
- People who have voluntarily given written consent to participate in this clinical trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have never received any prior treatment for small cell lung cancer.
- People who have previously been treated with the drugs Lurbinectedin or Paclitaxel.
- People diagnosed with limited-stage small cell lung cancer (cancer that has not spread widely).
- People with brain metastases (cancer that has spread to the brain) that are causing symptoms or are considered medically significant — though people with brain metastases that are stable and not causing symptoms may still be considered, provided any treatment for the brain metastases was completed at least 1 week before the first dose of the study drug.
- People who are currently taking certain medications that can affect heart rhythm, strongly suppress the immune system, or may cause lung inflammation — use of these medications during the treatment period is not allowed, and any exceptions would need to be discussed with the trial team first.
- People with active HIV infection, active hepatitis B, or active hepatitis C — though people with hepatitis B or C who meet certain conditions (such as undetectable virus levels or having been successfully treated) may still be considered eligible (confirm with trial site).
- People with active lung inflammation (interstitial lung disease) or a history of non-infectious lung inflammation that required steroid treatment, including cases related to immunotherapy or chemotherapy, or severe lung complications — though people who had a previous lung infection that has fully resolved may be considered (confirm with trial site).
- Women who are pregnant or breastfeeding.
- People who have had a significant heart condition in the past 12 months, such as heart failure, symptomatic heart artery disease, abnormal heart rhythms, or a heart attack.
- People who still have side effects from previous cancer treatment that have not returned to their normal baseline or reduced to a mild level.
- People who received any cancer treatment within the 14 days before the first dose of the study drug, or localised radiation therapy within the 7 days before the first dose.
- People who are known to have a serious allergic reaction to any of the study drugs.
- People who have any other condition that the trial doctor considers would make participation in the study unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Hye Ryun Kim, Severance Hospital
Phone: 82-2-2228-8125
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 April 2027
Where this trial is recruiting
🇰🇷 South Korea
Primary endpoints
Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.